The prostate, lung, colorectal and ovarian cancer screening trial: The prostate cancer screening results in context

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 12-17

  Berg, Christine D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CLINICAL STUDY; COHORT ANALYSIS; COLORECTAL CANCER; DATA ANALYSIS; DEMOGRAPHY; DIGITAL RECTAL EXAMINATION; GENETIC MARKER; HUMAN; INCIDENCE; LUNG CANCER; MOLECULAR GENETICS; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE LUNG COLORECTAL AND OVARIAN CANCER SCREENING TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCREENING TEST; UNITED STATES;

EARLY DETECTION OF CANCER; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 79957456530     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.531283     Document Type: Review

References (25)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer Clin J 2010;60:277-300. Epub 2010 Jul 7.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate-specifi c antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
3. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Control Clin Trials 2000;21(Suppl):251S-272S.
4. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(Suppl):273S-309S.
5. Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, et al. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal and Ovarian cancer screening trial. Am J Epidemiol 2007;165:874-81. (Pubitemid 46536660)
6. Hayes RB, Reding D, Kopp W, Subar A, Bhat N, Rothman R, et al. Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(Suppl):349S-355S.
7. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360: 1310-9.
8. Andriole GL, Levin DL, Crawford ED, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005;97:433-8. (Pubitemid 40528606)
9. Grubb RL III, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: Update on fi ndings from the initial four rounds of screening in a randomized trial. BJU Int 2008;102:1524-30.
10. Fleming JD, Cooper JS, Henson DE, et al., editors. AJCC cancer staging manual. 5 th ed. Philadelphia: Lippincott-Raven; 1997.
11. Pinsky PF, Black A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010;7: 303-11.
12. Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, et al. Prostate specifi c antigen changes as related to the initial prostate specifi c antigen: Data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2006;175:1286-90.
13. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, et al. Prostate-specifi c antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007;109: 1689-95. (Pubitemid 46595706)
14. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, et al. Repeat biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int 2007; 99:775-9. (Pubitemid 46439580)
15. Ford ME, Havstad SL, Demers R, Cole-Johnson C. Effects of false-positive prostate cancer screening results on subsequent prostate cancer screening behavior. Cancer Epidemiol Biomarkers Prev 2005;14:190-4. (Pubitemid 40165302)
16. Grubb RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, et al. Serum prostate-specifi c antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2009;18:748-51.
17. Koralek DO, Peters U, Andriole G, Reding D, Krish V, Subar A, et al. A prospective study of dietary alpha-linoleic acid and the risk of prostate cancer (United States). Cancer Causes Control 2006;17:783-91.
18. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, betacarotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006;98:245-54. (Pubitemid 43264708)
19. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:92-8.
20. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifi es a second risk locus at 8q24. Nat Genet 2007;39:645-9. Epub 2007 Apr 1. (Pubitemid 46676108)
21. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identifi ed in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-5. (Pubitemid 351311773)
22. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 2009;106:7933-8.
23. Xu J, Sun J, Kader AK, Lindstr öm S, Wiklund F, Hsu FC, et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009;69:1565-72.
24. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach. Med Decis Making 2008;28:323-31. (Pubitemid 351713299)
25. Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H, et al. Prevalence of prostate cancer among men with a prostate-specifi c antigen level of 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.